Strategy development for a manufacturing site following M&A in a pharmaceutical company

General Manager and Site Leader

Company:
Warner Chilcott Deutschland GmbH (part of Actavis)

Role:
General Manager of Warner Chilcott Deutschland GmbH and site leader of the Weiterstadt Site

Industry:
Pharmaceuticals

Revenue:
$13 Billion (Actavis), 100 Million € (Warner Chilcott Deutschland GmbH)

Employees:
Actavis: 10,000
Warner Chilcott: 350

Situation:
Integration following Acquisition by Actavis

Headquarters:
Ireland

Website:
www.actavis.com
(now part of Teva)

Responsibility(Revenue/Employees):

  • Site Revenue approx. 100 Mio € with 350 Employees

Context:

  • The local management team realized that the site needed a clear positioning and USP in order to be competitive in the new, large Actavis manufacturing network (with 25 sites running similar technologies)

Actions:

  • SWOT Analysis
  • Benchmarking with several sites of the Actavis network
  • Alignment with global management on path going forward: maximising utilization of existing technologies through transfer of currently outsourced volumes
  • Restructuring of the organisation (80 roles cut, approx >20% of the organization)
  • Analysis of all transferable products completed, business cases developed and brought to decision to global management

Result:

  • Utilization of existing equipment increased to maximum capacity (short term, until the generics business was sold to Teva)
  • Additional volume manufactured without overhead growth
Scroll to Top